We now understand the root causes of Alzheimer’s disease and we can knock out these toxic proteins. ProMis Neurosciences is developing precision medicine therapies for Alzheimer’s disease through the use of two proprietary discovery techniques. As we identify which target a patient has, we give them the antibody specifically directed against that target. We expect our first product to be a best in class therapeutic. These are key bullets in addressing and ultimately conquering Alzheimer’s disease.
The Company’s scientific foundation is centered on the growing consensus that prion forms of misfolded proteins are key drivers of neurodegenerative diseases. Prion forms of misfolded proteins are characterized by their neurotoxicity and ability to progressively spread throughout the brain, killing neurons. Numerous neurodegenerative diseases exhibit toxic, prion-like protein misfolding, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). Recent published evidence indicates that for a given misfolded protein there exist multiple prion-like strains, each strain representing a target against which specific therapeutics can be developed. ProMIS has identified distinct targets on strains of misfolded SOD1 in ALS and on misfolded strains of Amyloid beta in AD.
For more information on ProMis Neurosciences Inc. (PMN.TO) please fill out the form below.